

Resource Summary Report

Generated by [NIF](#) on Sep 11, 2026

SHP-77

RRID:CVCL_1693

Type: Cell Line

Proper Citation

RRID:CVCL_1693

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1693

Proper Citation: RRID:CVCL_1693

Description: Cell line SHP-77 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung small cell carcinoma

Defining Citation: [PMID:212181](#), [PMID:2985251](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:7736387](#), [PMID:9559344](#), [PMID:9815546](#), [PMID:12068308](#), [PMID:17426248](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28766886](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32586373](#), [PMID:35839778](#), [PMID:39154123](#)

Comments: Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SHP-77

Synonyms: SHP77, Shadyside Hospital Pittsburgh-77

Cross References: BTO:BTO_0003726, CLO:CLO_0009013, EFO:EFO_0002328, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2195, BioSample:SAMN03472563, BioSample:SAMN10988529, cancercellines:CVCL_1693,

Cell_Model_Passport:SIDM01078, ChEMBL-Cells:CHEMBL3308363, ChEMBL-Targets:CHEMBL612569, CLS:305498, Cosmic:724872, Cosmic:844577, Cosmic:877392, Cosmic:1152487, Cosmic:1759309, Cosmic:1995626, Cosmic:2125288, Cosmic:2239081, Cosmic-CLP:724872, DepMap:ACH-000790, ECACC:98110201, EGA:EGAS00001000978, GDSC:724872, GEO:GSM169447, GEO:GSM887569, GEO:GSM888652, GEO:GSM1374870, GEO:GSM1887913, GEO:GSM1887995, IARC_TP53:27237, IGRhCellID:SHP77, LiGeA:CCLE_667, LINCS_LDP:LCL-1823, NCI-DTP:SHP-77, PharmacoDB:SHP77_1375_2019, PRIDE:PXD011896, PRIDE:PXD030304, Progenetix:CVCL_1693, PubChem_Cell_line:CVCL_1693, Ubigene:YC-B049, Wikidata:Q54953391

ID: CVCL_1693

Record Creation Time: 20220427T221541+0000

Record Last Update: 20260905T182353+0000

Ratings and Alerts

No rating or validation information has been found for SHP-77.

No alerts have been found for SHP-77.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ott LF, et al. (2026) Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane. International journal of cancer, 158(6), 1713.

Patel UA, et al. (2026) CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer. Molecular cancer therapeutics, 25(1), 183.

Wang Y, et al. (2026) A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers. Cell, 189(13), 3922.

Iñáñez A, et al. (2025) The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer. International journal of molecular sciences, 26(3).

Teng M, et al. (2025) Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation. Cancer cell, 43(5), 891.

Nawa Y, et al. (2025) cAMP-Response Element (CRE)-Mediated Transcription by CRE-Binding Protein (CREB) Is Essential for Human Tryptophan Hydroxylase 2 Gene Expression. *Journal of neurochemistry*, 169(6), e70138.

Wang Z, et al. (2024) Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators. *Cancer cell*, 42(6), 1106.

O'Connell CE, et al. (2021) Combined Inhibition of p38MAPK and PIKfyve Synergistically Disrupts Autophagy to Selectively Target Cancer Cells. *Cancer research*, 81(11), 2903.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.